A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2014 Last checked against University Hospital Medical Information Network - Japan record.
- 05 Nov 2014 Status changed from completed to active, no longer recruiting.
- 09 Nov 2009 New trial record